+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating ziftomenib in Japanese patients with relapsed or refractory acute myeloid leukemia AML that has an NPM1 mutation. This Phase 2 study aims to assess the drugs effectiveness, safety, and how it behaves in the body. It is the first trial to administer ziftomenib to this patient group in Japan, with the goal of understanding its potential benefits for patients who have limited treatment options. Participants will take ziftomenib orally once daily. The study will monitor responses every 28 days, continuing treatment until the disease progresses or the patient withdraws. Several secondary measures will assess deeper remission rates, transfusion needs, and duration of response. The study also includes detailed monitoring of adverse events, drug levels in the blood, and patient health indicators during treatment and after discontinuation. During the trial, participants will have regular assessments including disease response evaluations every 28 days and safety checks. Follow-up will continue for up to one year after treatment ends to track overall survival and late effects. Participants will be monitored for side effects, changes in laboratory values, heart function, and overall physical status. The study duration varies but includes ongoing treatment and post-treatment observation to gather comprehensive data on ziftomenibs impact.

Age: 18Years +All GendersPhase 2
20 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
E

Actively Recruiting

Researchers are evaluating TAK-226 to see how it may improve symptoms of transfusion-dependent anemia in Japanese adults diagnosed with lower-risk myelodysplastic syndromes MDS. This Phase 2 study focuses on patients classified as very low, low, or intermediate risk according to established criteria. The study aims to assess the efficacy and safety of TAK-226, an investigational drug given by injection. During the Treatment Period, participants receive TAK-226 as a subcutaneous injection every four weeks for about one year. The study includes a Screening Period lasting up to six weeks, followed by a Safety Follow-Up Period of eight weeks after treatment ends. There is also a Long-Term Follow-Up Period lasting approximately five years from the first dose to monitor any lasting effects or side effects. Participants will visit the clinic approximately every two to four weeks during treatment. Researchers will measure outcomes such as the percentage of participants achieving transfusion independence or increases in hemoglobin levels over specific timeframes. In addition, various blood tests and safety assessments will be conducted throughout the study and follow-up periods. The total participation duration may last up to about six years.

Age: 18Years +All GendersPhase 2
21 locations
L

Actively Recruiting

Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.

Age: 55Years - 90YearsAll GendersPhase 3
252 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
R

Actively Recruiting

Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.

All AgesAll Genders
116 locations
C

Actively Recruiting

This clinical trial is studying adults who have experienced a small ischemic stroke, also known as lacunar stroke. It aims to determine if a combination of antiplatelet drugs dual antiplatelet therapy works as well as the standard treatment with intravenous tissue plasminogen activator rt-PA. Researchers also want to see if the combination reduces bleeding complications compared to rt-PA. Participants will be randomly assigned to receive either the dual antiplatelet therapy, which includes aspirin 200 mg and clopidogrel 300 mg, or intravenous rt-PA at a low dose of 0.6 mgkg alteplase, which is approved in Japan. The study follows a parallel design and is conducted at multiple centers. Treatment is given during the hyperacute phase within 4.5 hours of stroke onset. During the study, participants will be monitored for neurological status at 3 months after stroke through in-person visits, phone calls, or mail. Researchers will measure outcomes such as excellent recovery at 3 months, infarct growth, early neurological changes, stroke recurrence, and cost effectiveness. The total study period extends through March 2029, with primary outcome assessment at 3 months post-stroke.

Age: 18Years +All GendersPhase 4
29 locations
C

Actively Recruiting

Researchers are evaluating whether low treatment intensity 12 mLkghr or medium treatment intensity 25 mLkghr continuous kidney replacement therapy is more effective and safer for critically ill patients with acute kidney injury. This interventional clinical trial is sponsored by Jikei University School of Medicine and uses a randomized, parallel study design to compare these two dosing strategies in an intensive care setting. The study is conducted to understand the best approach to continuous renal replacement therapy for patients requiring this treatment. Participants are randomly assigned to receive either low-intensity or medium-intensity continuous hemodialysis andor hemofiltration, delivered through dialysate fluid and filtration replacement fluid. The study compares these two dosing levels, with interventions administered continuously while patients are in intensive care units. The trial includes phases 2 and 3 and is planned to complete by June 2030. During the study, participants are monitored for outcomes such as death and duration of kidney replacement therapy over 28 days or until hospital discharge, whichever comes first. Additional evaluations include ICU and hospital mortality, dialysis dependence, vasopressor-free days, ventilator-free days, serum creatinine levels, and urine output at kidney replacement therapy end. The total participation timeline extends up to hospital discharge or 90 days, with assessments performed at multiple time points to measure treatment effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
9 locations
I

Actively Recruiting

Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.

All AgesAll Genders
54 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of ONO-2017 cenobamate combined with other antiepileptic drugs in Japanese patients who have primary generalized tonic-clonic seizures. This phase III, open-label study focuses on patients aged 12 years or older who experience frequent generalized seizures as part of idiopathic generalized epilepsy. Participants will take cenobamate orally once daily alongside one to three other fixed-dose antiepileptic medications. The study aims to observe changes in seizure frequency over a 12-week maintenance period while monitoring safety and tolerability. Throughout the study, researchers will track seizure frequency and reduction rates using 28-day intervals during the maintenance phase. Participants will be assessed regularly for seizure control and any side effects. The study will continue until January 2027, allowing for ongoing evaluation of treatment effects and safety.

Age: 12Years +All GendersPhase 3
25 locations

1-10 of 15

1